Ionic liquids in drug delivery

Expert Opinion on Drug Delivery

Volumn 10, Issue 10, 2013, Pages 1367-1381

  Shamshina, Julia L ^a   Barber, Patrick S ^a   Rogers, Robin D ^a  

^a UNIVERSITY OF ALABAMA   (United States)

Author keywords

Active pharmaceutical ingredients; Crystallization; Drug delivery; Ionic liquid; Polymorphism

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ACICLOVIR; AMPHOTERICIN B; AMPICILLIN DERIVATIVE; CHLORAMPHENICOL; CURCUMIN; DIDECYLDIMETHYLAMMONIUM CHLORIDE; DOCUSATE SODIUM; DOPAMINE; IBUPROFEN; IONIC LIQUID; ITRACONAZOLE; LIDOCAINE DOCUSATE; OLIGOMER; PARACETAMOL; PRODRUG; RANITIDINE; RANITIDINE DERIVATIVE; RANITIDINE DOCUSATE; RITONAVIR; UNCLASSIFIED DRUG;

ACID BASE BALANCE; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; DRUG SOLUBILITY; HYDROGEN BOND; HYDROPHILICITY; LIPOPHILICITY; LIQUEFACTION; LIQUID CRYSTAL; MICELLE; MICELLIZATION; MICROEMULSION; REVIEW; STOICHIOMETRY;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IONIC LIQUIDS; PHARMACEUTICAL PREPARATIONS; SALTS; SOLUBILITY;

EID: 84884571043     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.808185     Document Type: Review

References (102)

1. Byrn S, Pfeiffer R, Ganey M, et al. Review. Pharmaceutical solids: A strategic approach to regulatory considerations. Pharm Res 1995;12:945-54
2. Lee DC, Webb ML. editors. Pharmaceutical analysis. Blackwell Pub Oxford UK; Boca Raton FL: 2003
3. ANDAs: Pharmaceutical Solid polymorphism chemistry, manufacturing, and controls information. Guidance for Industry. U.S. Department of Health and Human Services, FDA/Center for Drug Evaluation and Research, 2007. Available from: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm072866.pdf [Last accessed 26 March 13]
4. Giron D, Mutz M, Garnier S. Solid-state of pharmaceutical compounds impact of the ICH Q6 guideline on industrial development. J Therm Anal Calorim 2004;77:709-47
5. Brittain HG, Grant DJW. Effect of polymorphism and solid-state solvation on solubility and dissolution rate. In: Polymorphism in pharmaceutical solids. Brittain HG, editor. Marcel Dekker, Inc; New York: 1999. p. 279-330
6. Florence AT, Attwood D. Physicochemical principles of pharmacy. 2nd edition. Macmillan; Chapman & Hall, New York: 1988
7. Hook JR, Hall HE. Solid state physics. 2nd edition, John Wiley & Sons; 2010
8. Giron D. Investigation of polymorphism and pseudo-polymorphism in pharmaceutical by combined analytical techniques. J Therm Anal Calorim 2001;64:37-60
9. Ghielmetti G, Bruzzese T, Bianchi C, Recusani F. Relationship between acute toxicity in mice and polymorphic forms of polyene antibiotics. J Pharm Sci 1976;65:905-7
10. Bauer J, Spanton S, Henry R, et al. Ritonavir: An extraordinary example of conformational polymorphism. Pharm Res 2001;18:859-66
11. HIV and AIDS Activities. Office of Health and Constituent Affairs, U.S. Food and Drug Administration. 2013. Available from: Http://www.fda.gov/ ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm200179.htm [Last accessed 28 March 13]
12. Grant DJW. Theory and origin of polymorphism. In: Polymorphism in pharmaceutical solids. Brittain HG, editior Marcel Dekker; New York: 1999
13. Saifee M, Inamdar N, Dhamecha DL, et al. Drug polymorphism: A review. Int J Health Res 2009;2:289-306
14. Bighley LD, Berge SM, Monkhouse DC. Salt forms of drugs and absorption. In: Swarbrick J, Boylan JC, editors. In Encyclopedia of pharmaceutical technology. Marcel Dekker; New York: 1996
15. Haynes DA, Jones W, Motherwell WDS. Occurrence of pharmaceutically acceptable anions and cations in the Cambridge structural database. J Pharm Sci 2005;94:2111-20
16. Berge SM, Bighely LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci 1977;66:1-19
17. Gould PL. Salt selection for basic drugs. Int J Pharm 1986;33:201-17
18. Shan N, Zaworotko MJ. The role of cocrystals in pharmaceutical science. Drug Discov Today 2008;13:440-6
19. Frişçić T, Jones W. Benefits of cocrystallization in pharmaceutical materials science: An update. J Pharm Pharmacol 2010;62:1547-59
20. Aitipamula S, Banerjee R, Bansal AK, et al. Polymorphs, salts, and cocrystals: What's in a name? Cryst Growth Des 2012;12:2147-52
21. Kelley SP, Narita A, Holbrey JD, et al. Understanding the effects of ionicity in salts, solvates, co-crystals, ionic co-crystals, and ionic liquids, rather than nomenclature, is critical to understanding their behavior. Cryst Growth Des 2013;13:965-75
22. Ionic liquids: Industrial applications for green chemistry. In: Rogers RD, Seddon KR, editors. Ionic liquids: Industrial applications for green chemistry. ACS Symposium Series 818. American Chemical Society; Washington; DC: 2002
23. Bica K, Shamshina J, Hough WL, et al. Liquid forms of pharmaceutical cocrystals: Exploring the boundaries of salt formation. Chem Commun 2011;47:2267-9
24. Beyersdorff T, Schubert TJS, Welz-Biermann U, et al. Synthesis of ionic liquids. In: Endres F, Abbott AP, MacFarlane DR, editors. In Electrodeposition from ionic liquids. Wiley-VCH Verlag GmbH & Co. KGaA; 2008. p. 15-46
25. Clare B, Sirwardana A, Mac Farlane DR. Synthesis, purification and characterization of ionic liquids. Top Curr Chem 2010;290:1-40
26. Gordon CM, Muldoon MJ. Synthesis and purification: Synthesis of ionic liquids. In: Wasserscheid P, Welton T, editor. Ionic Liq. Synth. 2nd edition. Wiley-VCH Verlag GmbH & Co. KGaA; 2008. p. 7-25
27. Hullio AA, Mastoi GM. Designing, synthesis and applications of task specific ionic liquids. Orient J Chem 2011;27:1591-612
28. MacFarlane DR, Forsyth SA, Golding J, et al. Ionic liquids based on imidazolium, ammonium and pyrrolidinium salts of the dicyanamide anion. Green Chem 2002;4:444-8
29. Bresme F, González-Melchor M, Alejandre J. Influence of ion size asymmetry on the properties of ionic liquid-vapour interfaces. J Phys Condens Matter 2005;17:S3301-7
30. Jiménez AE, Berm-udez MD, Iglesias P, et al. 1-N-alkyl-3- methylimidazolium ionic liquids as neat lubricants and lubricant additives in steel-aluminium contacts. Wear 2006;260:766-82
31. Lu Q, Wang H, Ye C, et al. Room temperature ionic liquid 1-ethyl-3-hexylimidazolium-bis (trifluoromethylsulfonyl)-imide as lubricant for steel-steel contact. Tribol Int 2004;37:547-52
32. Mu Z, Liu W, Zhang S, et al. Functional room-temperature ionic liquids as lubricants for an aluminum-on-steel system. Chem Lett 2004;33:524-5
33. Ye C, Liu W, Chen Y, et al. Room-temperature ionic liquids: A novel versatile lubricant. Chem Commun 2001;21:2244-5
34. Klapotke TM, Holl G. The greening of explosives and propellants using high-energy nitrogen chemistry. Green Chem 2001;3:G75
35. Pernak J, Syguda A, Mirska I, et al. Choline-derivative-based ionic liquids. Chem Eur J 2007;13:6817-27
36. Hough WL, Smiglak M, Rodríguez H, et al. The third evolution of ionic liquids: Active pharmaceutical ingredients. New J Chem 2007;31:1429-36
37. Hough WL, Rogers RD. Ionic liquids then and now: From solvents to materials to active pharmaceutical ingredients. Bull Chem Soc Jpn 2007;80:2262-9
38. Martin JD. Structure-property relationships in ionic liquids. In: Rogers RD, Seddon KR, editors. In Ionic liquids: Industrial applications for green chemistry. ACS Symposium Series 818. American Chemical Society; Washington, DC: 2002
39. Trohalaki S, Pachter R, Drake G et al. Quantitative structure-property relationships for melting points and densities of ionic liquids. Available from: Http://www.dtic.mil/cgi-bin/GetTRDoc? AD=ADA430749 [Last accessed 28 March 13]
40. Rogers RD, Daly DT, MacFarlane D, et al. Dual functioning ionic liquids and salts thereof. PCT Int Appl. WO 2010/078300 (2010), US 2012/0046244 A1; 2012
41. Rogers RD, Daly DT, Swatloski RP, et al. Multifunctional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional and energetic ingredients. U.S. Patent No. 8,232,265; PCT/US2006/039454; WO 2007/044693 A2 (2007), MX 301158; 2012
42. Rogers RD, Rijksen C, Daly DT, et al. Compounds comprising two or more biologically functional ions and method of treating Parkinson's Disease. PCT Int. Appl. WO 2010078258 A1 20100708; 2010
43. Ferraz R, Branco LC, Marrucho IM, et al. Development of novel ionic liquids based on ampicillin. MedChemCommun 2012;3:494-7
44. Rebelo LPN, Lopes JNC, Esperança JMSS, et al. Accounting for the unique, doubly dual nature of ionic liquids from a molecular thermodynamic and modeling standpoint. Acc Chem Res 2007;40:1114-21
45. Fei Z, Geldbach TJ, Zhao D, et al. From dysfunction to bis-function: On the design and applications of functionalised ionic liquids. Chem Eur J 2006;12:2122-30
46. Dean PM, Turanjanin J, Yoshizawa-Fujita M, et al. Exploring an anti-crystal engineering approach to the preparation of pharmaceutically active ionic liquids. Cryst Growth Des 2009;9:1137-45
47. Bica K, Rijksen C, Nieuwenhuyzen M, et al. In search of pure liquid salt forms of aspirin: Ionic liquid approaches with acetylsalicylic acid and salicylic acid. Phys Chem Chem Phys 2010;12:2011-17
48. Suresh C, Zhao H, Gumbs A, et al. New ionic derivatives of betulinic acid as highly potent anti-cancer agents. Bioorg Med Chem Lett 2012;22:1734-8
49. Bica K, Rogers RD. Confused ionic liquid ions - a " liquification" and dosage strategy for pharmaceutically active salts. Chem Commun 2010;46:1215-17
50. Yoshizawa M, Xu W, Angell CA. Ionic liquids by proton transfer: Vapor pressure, conductivity, and the relevance of DpKa from aqueous solutions. J Am Chem Soc 2003;125:15411-19
51. Ettmayer P, Amidon GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47:2393-404
52. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 2007;59:677-94
53. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: Design and clinical applications. Nat Rev Drug Discov 2008;7:255-70
54. Rautio J. Prodrug strategies in drug design. In: Rautio J, editor. In Prodrugs and targeted delivery: Towards better ADME properties. Wiley-VCH Verlag GmbH & Co. KgaA; Weinheim: 2010
55. Aguiar AJ, Krc J Jr, Kinkel AW, et al. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. J Pharm Sci 1967;56:847-53
56. Cojocaru OA, Bica K, Gurau G, et al. Prodrug ionic liquids: Functionalizing neutral active pharmaceutical ingredients to take advantage of the ionic liquid form. MedChemCommun 2013;4:559-63
57. Davis JH, Fox PA. From curiosities to commodities: Ionic liquids begin the transition. Chem Commun 2003;1209-12
58. Nishi N, Kawakami T, Shigematsu F, et al. Fluorine-free and hydrophobic room-temperature ionic liquids, tetraalkylammonium bis(2-ethylhexyl) sulfosuccinates, and their ionic liquid-water two-phase properties. Green Chem 2006;8:349-55
59. Huddleston JG, Willauer HD, Swatloski RP, et al. Room temperature ionic liquids as novel media for "clean" liquid-liquid extraction. Chem Commun 1998;1765-6
60. Mizuuchi H, Jaitely V, Murdan S, et al. Room temperature ionic liquids and their mixtures: Potential pharmaceutical solvents. Eur J Pharm Sci 2008;33:326-31
61. Jaitely V, Karatas A, Florence AT. Water-immiscible room temperature ionic liquids (RTILs) as drug reservoirs for controlled release. Int J Pharm 2008;354:168-73
62. McCrary PD, Beasley PA, Gurau G, et al. Drug specific, tuning of an ionic liquid's hydrophilic-lipophilic balance to improve water solubility of poorly soluble active pharmaceutical ingredients. New J Chem 2013;DOI: 10.1039/C3NJ00454F
63. Date AA, Patravale VB. Microemulsions: Applications in transdermal and dermal delivery. Crit Rev Ther Drug Carrier Syst 2007;24:547-96
64. Gupta S, Moulik SP. Biocompatible microemulsions and their prospective uses in drug delivery. J Pharm Sci 2008;97:22-45
65. Eastoe J, Gold S, Rogers SE, et al. Ionic liquid-in-oil microemulsions. J Am Chem Soc 2005;127:7302-3
66. Moniruzzaman M, Tahara Y, Tamura M, et al. Ionic liquid-assisted transdermal delivery of sparingly soluble drugs. Chem Commun 2010;46:1452-4
67. Moniruzzaman M, Tamura M, Tahara Y, et al. Ionic liquid-in-oil microemulsion as a potential carrier of sparingly soluble drug: Characterization and cytotoxicity evaluation. Int J Pharm 2010;400:243-50
68. Moniruzzaman M, Kamiya N, Goto M. Ionic liquid based microemulsion with pharmaceutically accepted components: Formulation and potential applications. J Colloid Interface Sci 2010;352:136-42
69. Patra D, Barakat C. Unique role of ionic liquid [bmim][BF4] during curcumin-surfactant association and micellization of cationic, anionic and non-ionic surfactant solutions. Spectrochim Acta A 2011;79:1823-8
70. Ghatak C, Rao VG, Mandal S, et al. An understanding of the modulation of photophysical properties of curcumin inside a micelle formed by an ionic liquid: A new possibility of tunable drug delivery system. J Phys Chem B 2012;116:3369-79
71. Mahajan S, Sharma R, Mahajan RK. An investigation of drug binding ability of a surface active ionic liquid: Micellization, electrochemical, and spectroscopic studies. Langmuir 2012;28:17238-46
72. Gordian M, Singh N, Zemmel R, et al. Why products fail in phase III. In Vivo 2006;4:49-54
73. Patel ND. An emerging technique for poorly soluble drugs: Self-emulsifying drug delivery system. Int J Pharm Biol Arch 2011;2:621-9
74. Vallet-Regi M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed 2007;46:7548-58
75. Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. Int J Pharm 1997;154:123-40
76. Ettmayer P, Amidon GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47:2393-404
77. Stella VJ. Some thoughts and current issues. J Pharm Sci 2010;99:4755-65
78. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev 2007;59:603-16
79. Banerjee R, Bhatt PM, Ravindra NV, et al. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities. Cryst Growth Des 2005;5:2299-309
80. Patil SK, Wagh KS, Parik VB, et al. Strategies for solubility enhancement of poorly soluble drugs. Int J Pharm Sci Rev Res 2011;8:74-80
81. Remenar JF, Morissette SL, Peterson ML, et al. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 2003;125:8456-7
82. Childs SL, Chall LJ, Dunlap JT, et al. Crystal engineering approach to forming cocrystals of amine hydrochloride with organic acids. J Am Chem Soc 2004;126:13335-42
83. Trask AV, Motherwell WDS, Jones W. Pharmaceutical cocrystallization: Engineering a remedy for caffeine hydration. Cryst Growth Des 2005;5:1013-21
84. Alhalaweh A, George S, Basavoju S, et al. Pharmaceutical cocrystals of nitrofurantoin: Screening, characterization and crystal structure analysis. CrystEngComm 2012;14:5078-88
85. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60
86. Singh MC, Sayyad AB, Sawant SD. Review on various techniques of solubility enhancement of poorly soluble drugs with special emphasis on solid dispersion. J Pharm Res 2010;3:2494-501
87. Choucair A, Eisenburg A. Interfacial solubilization of model amphiphilic molecules in block copolymer micelles. J Am Chem Soc 2003;125:11993-2000
88. Smiglak M, Bridges NJ, Dilip M, et al. Formation direct, atom efficient, and halide free syntheses of azolium azolate energetic ionic liquids and their eutectic mixtures, and method for determining eutectic composition. Chem Eur J 2008;14:11314-19
89. Smiglak M, Metlen A, Rogers RD. The second evolution of ionic liquids: From solvents and separations to advanced materials-energetic examples from the ionic liquid cookbook. Acc Chem Res 2007;40:1182-92
90. Hamamoto H, Miwa Y. Tape preparation comprising etodolac in ionic liquid form. EP 2233138 A1, WO2009075094; 2010
91. Chemical name: 2-(diethylammonium)-N-(2,6-dimethylphenyl)acetamide (RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetate)
92. Pareek AMD, Chandurkar N, Ambade R, et al. Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: A randomized, double-blind comparative evaluation. Clin J Pain 2010;26:561-6
93. Liang TH, Hsu PN. Double blind randomized comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. Curr Med Res Opin 2003;19:336-41
94. Dick WC, Bulstra S, Schardijin GH, et al. Safety and efficacy of etodolac compared with piroxicam in patients with degenerative joint disease of the knee. Clin Ther 1992;14:517-26
95. Chikanza IC, Clarke B, Hopkins R, et al. A comparative study of efficacy and toxicity of etodolac and naproxen in the treatment of osteoarthritis. Br J Clin Pract 1994;48:67-9
96. MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder, ClinicalTrials.gov Identifier: NCT01161615. Available from: Http://clinicaltrials.gov/show/NCT01161615 [Last accessed 17 May 13]
97. MEDRx news release. Available from: Http://www.medrx.co.jp/english/ newsrelease.html [Last accessed 17 May 13]
98. Yoshizawa M, Xu W, Angell CA. Ionic liquids by proton transfer: Vapor pressure, conductivity, and the relevance of DeltapKa from aqueous solutions. J Am Chem Soc 2003;125:15411-19
99. Cojocaru OA, Siriwardana A, Gurau G, et al. Pharmaceutically active supported ionic liquid phases. In: Fehrmann R, Haumann M, Riisager A, editor. Book chapter in supported ionic liquids -fundamentals and applications, Wiley-VCH, ISBN-13: 978-3527324293; Weinheim, Germany: 2013, in press.
100. Riisager A, Fehrmann R, Rogers RD, Gurau G. Enhancing the thermal stability of ionic compounds by immobilization on porous solid support. PCT Int. Appl. WO 2013030299 A1
101. Riisager A, Fehrmann R, Rodriguez R, et al. Biologically active compounds supported on solid carrier such as silica for controlled release and improved thermal stability. PCT Int. Appl. WO 2011110662; 2011
102. Bica K, Rodríguez H, Gurau G, et al. Pharmaceutically active ionic liquids with solids handling, enhanced thermal stability, and fast release. Chem Commun 2012;48:5422-4